AstraZeneca Announces Positive Interim Results for Ultomiris in I CAN Phase III Trial

AstraZeneca (AZN) reported positive results from a prespecified interim analysis of the I CAN Phase III trial, showing Ultomiris significantly reduced proteinuria in adults with IgAN. The trial's primary endpoint was met, and the company plans to seek accelerated approval. The safety profile of Ultomiris remained consistent with prior data.

By Noor Ul Ain Rehman Mon, April 27, 2026 at 9:05 AM GMT+3 2 min read · Yahoo Finance · April 27, 2026, 06:05 UTC

Tickers: $AZN

Topics: AstraZeneca clinical trials drug development IgAN pharmaceuticals Ultomiris

Read the full article at Yahoo Finance

More World news

Nebius Group Reports Massive Q3 2026 Revenue Growth Driven by AI Cloud Expansion Motley Fool · November 12, 2026, 17:29 UTC
Reagan Institute Launches Society of Fellows to Support Early Career Scholars PR Newswire · November 12, 2026, 17:32 UTC
Global Asset Management Group Signs LOI for $100 Million Affordable Housing Portfolio in Washington, D.C. PR Newswire · November 12, 2026, 17:30 UTC
U.S. Air Conditioner and Heat Pump Shipments Increase 27.3% in September Seeking Alpha · November 12, 2026, 17:27 UTC
Nvidia CEO Jensen Huang Resigns Amid Intelligence Probe Seeking Alpha · November 12, 2026, 17:27 UTC
Oklo and Centrus Energy Sign Multi-Year HALEU Fuel Supply Agreements for Ohio Nuclear Campus Seeking Alpha · November 12, 2026, 17:28 UTC
IRS Announces Increased 401(k) Contribution Limits for 2027 CNBC · November 12, 2026, 17:23 UTC
Bit Digital Announces $865 Million Contract and Commencement of 40MW Billing Seeking Alpha · November 12, 2026, 17:20 UTC
Nvidia CEO Jensen Huang Resigns Amid Investigation and Personal Allegations Motley Fool · November 12, 2026, 17:20 UTC
Argus Research Upgrades Republic Services to Buy Seeking Alpha · November 12, 2026, 17:16 UTC